The first bundle of four molecules and eight related brands, focusing on the two main therapeutic areas uro-oncology and gynaecology, was bought in October 2019. The APIs of the referring products are Buserelin, Oxybutynin, Nilutamide and Gonadorelin.
"This investment will enhance the diversification of our product portfolio”, said CHEPLAPHARM’s CEO Sebastian F. Braun. “Furthermore, this agreement matches perfectly with our internationally oriented business strategy."
The second bundle was bought at the end of May 2020. The package includes 11 molecules and 17 related brands, focusing on the therapeutic areas cardiology and intensive care, and are on sale in about 25 countries. The main APIs are Betaxolol and Heparin-Calcium. Five molecules of this portfolio are part of the World Health Organization list of essential medicines. Until all acquired marketing authorizations in the respective countries have been transferred to CHEPLAPHARM, the production and distribution will be ensured by the seller.
Edeltraud Lafer, Chief Operating Officer at CHEPLAPHARM concludes: "These recent acquisitions will help ensure continued patient access to multiple essential medicines in many countries."
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com